Analysis of Cetuximab-treated HNSCC patients suffering from recurrent metastatic disease [34] showed that patients with low ITGB4 expression were at higher relative risk to have short PFS. This evidence concerns the gene ITGB4 and head and neck squamous cell carcinoma.